These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Differential effect of clofibrate on adriamycin cytotoxicity in P388 murine leukemia cells sensitive and resistant to adriamycin.
    Author: Chitnis M, Parekh H, Satyamoorthy K.
    Journal: Tumori; 1989 Apr 30; 75(2):100-5. PubMed ID: 2741213.
    Abstract:
    Clofibrate (CPIB), an antihyperlipidemic agent, was utilized as a drug response modulator to modify the cytotoxicity of adriamycin (ADR) in vitro in P388 murine lymphocytic leukemia cells sensitive (P388/S) and resistant (P388/ADR) to ADR. CPIB elicited concentration and time dependent DNA biosynthesis inhibition which was completely reversible up to the concentration of 0.0025% in P388/S. However, only a partial reversibility of DNA biosynthesis inhibition was observed in P388/ADR cells treated with 0.0025% of CPIB. In both P388/S and P388/ADR there was complete and irreversible DNA biosynthesis inhibition at CPIB concentration of 0.005%. These findings were further confirmed by tumorigenicity analysis. CPIB was ineffective in altering ADR cytotoxicity in P388/S cells. However, in P388/ADR, CPIB enhanced ADR cytotoxicity at the lower concentrations of ADR and decreased the cytotoxicity upon increase in ADR concentrations. The enhancement in ADR cytotoxicity by CPIB in P388/ADR was due to increased ADR accumulation which was absent in P388/S cells. The present findings suggest the utility of CPIB as a selective agent to circumvent ADR resistance and to reduce host toxicity due to the drug.
    [Abstract] [Full Text] [Related] [New Search]